What is ABK Biomedical?
ABK Biomedical is a specialized medical technology firm dedicated to the research, development, and commercialization of innovative therapies for benign and malignant hypervascular tumors. The company distinguishes itself through a deep intellectual property portfolio centered on inorganic polymer microspheres and sophisticated administration systems. By maintaining internal R&D and manufacturing capabilities, ABK Biomedical ensures rigorous quality control over its investigational products, such as the Eye90 microspheres. The firm operates at the intersection of material science and oncology, aiming to provide clinicians with precise, effective tools for interventional radiology and embolotherapy.
How much funding has ABK Biomedical raised?
ABK Biomedical has raised a total of $104M across 4 funding rounds:
Series A
$9M
Series B
$30M
Series C
$30M
Series D
$35M
Series A (2017): $9M, investors not publicly disclosed
Series B (2019): $30M, investors not publicly disclosed
Series C (2022): $30M supported by Eight Roads, F-Prime Capital Partners, and Santé Ventures
Series D (2025): $35M featuring Santé Ventures, Eight Roads Ventures, J.P. Morgan Asset Management, and F-Prime Capital
Key Investors in ABK Biomedical
Santé Ventures
A venture capital firm focused on early-stage healthcare and technology, managing significant capital to support innovations in biotech, medtech, and healthtech.
Eight Roads Ventures
A global venture capital firm specializing in growth-stage investments across the real estate, technology, and healthcare sectors.
J.P. Morgan Asset Management
A global financial services leader providing comprehensive investment management and wealth advisory solutions to institutional and individual clients.
What's next for ABK Biomedical?
With the successful closure of this latest funding round, ABK Biomedical is poised to enter a critical phase of commercialization and clinical validation. The strategic capital will likely be deployed to advance the Eye90 microspheres through ongoing clinical trials and to navigate the complex regulatory requirements necessary for market entry. As the company scales its manufacturing infrastructure, it remains focused on its core mission of improving patient outcomes through technological innovation. Future growth will likely hinge on the successful translation of its proprietary embolotherapy platform into standard-of-care clinical practice, further solidifying its position as a leader in the medtech sector.
See full ABK Biomedical company page
